| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | James Douketis | Q100404477 |
| P2093 | author name string | Mark Crowther | |
| Philip S Wells | |||
| Jennifer A Pereira | |||
| Heather McDonald | |||
| Anne M Holbrook | |||
| Renee Labiris | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 1095-1106 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | Systematic overview of warfarin and its drug and food interactions | |
| P478 | volume | 165 |
| Q38647787 | 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation |
| Q38238911 | A Comprehensive Review of Potential Warfarin-Fruit Interactions |
| Q92103661 | A Framework Model for a Contextualized and Integrated Warfarin Therapy Case in a Master of Pharmacy Program |
| Q34349297 | A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics |
| Q89467632 | A Novel LC-MS/MS Assay for Quantification of Des-carboxy Prothrombin and Characterization of Warfarin-Induced Changes |
| Q36085531 | A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation |
| Q35828065 | A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma |
| Q46456544 | A cross-sectional study of the Anticoagulation Clinic in RIPAS Hospital, Brunei |
| Q38087192 | A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice |
| Q37014216 | A population-based assessment of the drug interaction between levothyroxine and warfarin |
| Q43478643 | A probable clinically significant interaction between warfarin and cloxacillin: three case reports. |
| Q41996857 | A review of drug-drug interactions in older HIV-infected patients |
| Q21090750 | A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines |
| Q94453403 | A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| Q34177159 | AREDS Formula, Warfarin, and Bleeding: A Case Report from the Michigan Anticoagulation Quality Improvement Initiative |
| Q41903969 | Acute warfarin toxicity: An unanticipated consequence of amoxicillin/clavulanate administration |
| Q36277366 | Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation |
| Q33162458 | Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. |
| Q34644792 | Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. |
| Q37871561 | Adverse effects of concentrated green tea extracts |
| Q43271666 | Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study |
| Q39088514 | Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. |
| Q38118483 | Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. |
| Q34580602 | Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. |
| Q36002461 | An automated database case definition for serious bleeding related to oral anticoagulant use. |
| Q43191814 | An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone |
| Q36108384 | An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation |
| Q27027953 | An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation |
| Q34147587 | An integrative method for scoring candidate genes from association studies: application to warfarin dosing |
| Q37233377 | Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. |
| Q39326279 | Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism |
| Q59503156 | Analysis of the quality of prescriptions at a cardiovascular ward in Brazil: a pilot study |
| Q39856545 | Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: Has Prescribing Improved? |
| Q93145673 | Anticoagulants for cancer-associated ischemic stroke |
| Q33435357 | Anticoagulation Therapy in Patients with Chronic Kidney Disease |
| Q38670098 | Anticoagulation-related nephropathy |
| Q38909618 | Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke |
| Q38081257 | Antithrombotics for stroke prevention in non-valvular atrial fibrillation: an update |
| Q38503308 | Antivitamins for Medicinal Applications |
| Q37987051 | Apixaban: an oral direct factor-xa inhibitor |
| Q35790384 | Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
| Q39458922 | Assessment of Oral Anticoagulant Use in Residents of Long-Term Care Homes: Evidence for Contemporary Suboptimal Use. |
| Q39321699 | Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation. |
| Q38726633 | Assessment of the Impact of L-Thyroxine Therapy on Bleeding Risk in Patients Receiving Vitamin K Antagonists. |
| Q36350029 | Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis |
| Q50499001 | Atrial fibrillation and stroke prevention: is warfarin still an option? Yes: Debate at the Controversies in Neurology Congress, Beijing, October 2011. |
| Q35633727 | Azathioprine-induced warfarin resistance |
| Q42742462 | Be careful before prescribing warfarin and octreotide together: a new drug-drug interaction report. |
| Q43762811 | Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology. |
| Q36017235 | Best practice in primary care pathology: review 8. |
| Q42154770 | Bleeding associated with coadministration of rivaroxaban and clarithromycin |
| Q88599305 | Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation |
| Q30356138 | Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries. |
| Q57252900 | Bleeding risk with oral anticoagulation - new frontiers and new questions |
| Q37659809 | Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice |
| Q89556414 | CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients |
| Q40174813 | CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. |
| Q34026257 | CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement |
| Q36101603 | Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case |
| Q38156452 | Carbonyl reduction pathways in drug metabolism. |
| Q38237024 | Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections |
| Q43117540 | Checklists for the use of novel oral anticoagulants by the front-line clinician |
| Q38372780 | Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation |
| Q36327107 | Clarithromycin extended-release in community-acquired respiratory tract infections |
| Q36981935 | Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study |
| Q37060478 | Clinical factors influencing the sensitivity to warfarin when restarted after surgery |
| Q36025053 | Clinical risk management of herb-drug interactions |
| Q36968781 | Coagulation assessment with the new generation of oral anticoagulants |
| Q40979010 | Combination of lenalidomide and low-dose dexamethasone therapy promotes the anticoagulant activity of warfarin in patients with immunoglobulin light-chain amyloidosis |
| Q43258069 | Comment: fatal intracranial bleed potentially due to a warfarin and influenza vaccine interaction |
| Q35196123 | Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study |
| Q36896927 | Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses |
| Q92867382 | Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study |
| Q38129733 | Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review |
| Q37077528 | Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area |
| Q90731510 | Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study |
| Q90150695 | Comparison of Two Different Techniques Of Warfarin Dosing Determination - A Chemometrics Study |
| Q33912263 | Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system |
| Q33575568 | Completeness of prescription information in US commercial claims databases |
| Q40148421 | Comprehensive characterization of rodenticides in wastewater by liquid chromatography-tandem mass spectrometry |
| Q43970773 | Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. |
| Q37015862 | Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults |
| Q36219247 | Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support |
| Q37833073 | Contemporary management of transient ischemic attack: role of the pharmacist |
| Q38148500 | Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants |
| Q36064839 | Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses |
| Q35880928 | Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction |
| Q84047213 | Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference |
| Q37554661 | Crystal structure of 4-(4b,8a-di-hydro-9H-pyrido[3,4-b]indol-1-yl)-7-methyl-2H-chromen-2-one |
| Q37005962 | Crystal structures of 4-methyl-2-oxo-2H-chromene-7,8-diyl di-acetate and 4-methyl-2-oxo-2H-chromene-7,8-diyl bis-(pent-4-ynoate) |
| Q37781464 | Current Thoughts on Treatment of Patients Receiving Anticoagulation Therapy |
| Q37990564 | Current anticoagulant safety |
| Q37330311 | Current issues in thromboprophylaxis in the elderly |
| Q37140198 | Current strategies to minimize the bleeding risk of warfarin |
| Q36855608 | Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G |
| Q35728256 | DBU-promoted carboxylative cyclization of o-hydroxy- and o-acetamidoacetophenone |
| Q38537977 | Dabigatran for the treatment of venous thromboembolism |
| Q88594108 | Design, Synthesis and Antifungal Activity of Coumarin Ring-Opening Derivatives |
| Q36707903 | Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients |
| Q47602971 | Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®. |
| Q36956314 | Dietary supplements, herbs and oral anticoagulants: the nature of the evidence |
| Q39064465 | Differences between warfarin and new oral anticoagulants in dental clinical practice. |
| Q51107902 | Dosage individualization of warfarin using artificial neural networks. |
| Q37848142 | Drug and dietary interactions of warfarin and novel oral anticoagulants: an update |
| Q44848854 | Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database |
| Q24681312 | Drug interactions with warfarin: what clinicians need to know |
| Q52369980 | Drug-drug interactions involving antidepressants: focus on desvenlafaxine. |
| Q33387312 | Drug-induced hematologic syndromes |
| Q34609020 | Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. |
| Q37521378 | Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. |
| Q38672876 | Edoxaban in patients with atrial fibrillation |
| Q24202280 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation |
| Q24234691 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation |
| Q36335405 | Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. |
| Q38514821 | Effect of cocoa products and flavanols on platelet aggregation in humans: a systematic review. |
| Q38087565 | Effect of flavonoids on circulating levels of TNF-α and IL-6 in humans: a systematic review and meta-analysis. |
| Q37073166 | Effect of galantamine on platelet functions in healthy elderly people |
| Q48905886 | Effect of gene polymorphims on the warfarin treatment at initial stage. |
| Q28276514 | Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin |
| Q41907990 | Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients |
| Q37997104 | Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy |
| Q37965570 | Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review |
| Q37481222 | Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs |
| Q31119748 | Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data |
| Q92423492 | Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus |
| Q37787307 | Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. |
| Q38809948 | Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients |
| Q39300348 | Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis |
| Q50509187 | Effects of safflower injection on the pharmacodynamics and pharmacokinetics of warfarin in rats. |
| Q46251562 | Effects of warfarin and L-carnitine on hemostatic function and oxidative stress in streptozotocin-induced diabetic rats |
| Q41910923 | Enhanced Interaction between Warfarin and High-Dose Ketoconazole: A Case Report |
| Q57032616 | Establishing a Flow Process to Coumarin-8-Carbaldehydes as Important Synthetic Scaffolds |
| Q33410725 | Estimation of the warfarin dose with clinical and pharmacogenetic data |
| Q46778368 | Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients |
| Q34593514 | Evaluation of a potential tigecycline-warfarin drug interaction |
| Q34720391 | Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting |
| Q47795702 | Evaluation of food-drug interaction of guava leaf tea. |
| Q36697798 | Evaluation of knowledge of Health care professionals on warfarin interactions with drug and herb medicinal in Central Saudi Arabia |
| Q42734047 | Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients |
| Q64327453 | Evaluation of the impact of body mass index on warfarin requirements in hospitalized patients |
| Q24632951 | Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q28218136 | Evidence-based use of medications in patients with coronary artery disease in a rural Australian community |
| Q91782301 | Expanding ambulatory care pharmacy services beyond anticoagulation |
| Q48830924 | Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. |
| Q53142338 | Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. |
| Q38903357 | Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants |
| Q33617751 | Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk |
| Q42105607 | Follow-up results of acute portal and splenic vein thrombosis with or without anticoagulation therapy after hepatobiliary and pancreatic surgery |
| Q36808017 | Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents |
| Q36792774 | Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look |
| Q43266149 | Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin |
| Q43268895 | Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients |
| Q48190936 | Gingival bleeding, a possible "serious" adverse drug reaction: An observational study in the French PharmacoVigilance Database |
| Q36509202 | Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases |
| Q28066527 | Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism |
| Q35153652 | HIV-Associated Venous Thromboembolism |
| Q36402506 | Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management |
| Q37955199 | Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants |
| Q35131841 | High-risk antimicrobial prescriptions among ambulatory patients on warfarin. |
| Q53080284 | How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting. |
| Q37113990 | How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation? |
| Q33606800 | Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin |
| Q42922983 | Hyperprothrombinemia as a Result of a Possible Warfarin and Intravaginal Miconazole Interaction |
| Q50918683 | Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital. |
| Q33634312 | Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy |
| Q46702584 | Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment |
| Q87866410 | Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke |
| Q37676340 | Implementation of pharmacist-managed anticoagulation clinic in a saudi arabian health center |
| Q48352011 | In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen |
| Q51190068 | Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. |
| Q36768389 | Inappropriate prescribing in the elderly |
| Q33585000 | Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study |
| Q37195550 | Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin |
| Q47330864 | Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches |
| Q49378467 | Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. |
| Q35557149 | Infrequent older adult-primary care provider discussion and documentation of dietary supplements |
| Q38084539 | Integrating dietary supplements into cancer care |
| Q33550741 | Integration of genetic, clinical, and INR data to refine warfarin dosing |
| Q51439071 | Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. |
| Q38768207 | Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review |
| Q83060994 | Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial |
| Q37498881 | Interaction between gemfibrozil and warfarin: case report and review of the literature. |
| Q36910151 | Interaction between lopinavir/ritonavir and warfarin |
| Q37234094 | Interaction between statins and clopidogrel: is there anything clinically relevant? |
| Q36952010 | Interaction between warfarin and nafcillin: case report and review of the literature |
| Q36745175 | Interaction potential between cranberry juice and warfarin |
| Q35491511 | Is aspirin use associated with age-related macular degeneration? A meta-analysis. |
| Q48641644 | Is point-of-care accurate for indicating thrombolysis in anticoagulated patients on oral anticoagulation treatments? |
| Q36670620 | Is the HAS-BLED score useful in predicting post-extraction bleeding in patients taking warfarin? A retrospective cohort study |
| Q88961925 | Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stro |
| Q35698491 | Lack of Association of Clinical Factors (SAMe-TT2R2) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality |
| Q35161650 | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
| Q36484975 | Leflunomide and warfarin interaction: case report and review of the literature |
| Q36496639 | Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study |
| Q42907039 | Management of Pulmonary Embolism: 2010 State-of-the-Art Update |
| Q46123423 | Management of patients on warfarin by general dental practitioners in South West Wales: continuing the audit cycle |
| Q37621554 | Management of venous thromboembolism and the potential to impact overall survival in patients with cancer |
| Q36590609 | Management of venous thromboembolism in the elderly |
| Q26991728 | Managing anticoagulation for atrial fibrillation: current issues and future strategies |
| Q89448981 | Matrix Gla protein regulates adipogenesis and is serum marker of visceral adiposity |
| Q28478229 | Measurement of warfarin in the oral fluid of patients undergoing anticoagulant oral therapy |
| Q36303746 | Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport. |
| Q53772418 | Microwave-assisted Synthesis and antifungal activity of coumarin[8,7-e][1,3]oxazine derivatives. |
| Q37365278 | Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. |
| Q38831847 | New anticoagulants for the treatment of venous thromboembolism |
| Q38065063 | New avenues for anticoagulation in atrial fibrillation |
| Q40580512 | New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring |
| Q38287155 | Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now? |
| Q99583860 | Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation |
| Q36443814 | Novel anticoagulants in atrial fibrillation stroke prevention |
| Q33828711 | Novel microtubule-targeted agent 6-chloro-4-(methoxyphenyl) coumarin induces G2-M arrest and apoptosis in HeLa cells |
| Q34627780 | Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism |
| Q39601797 | Nystatin and miconazole: pharmacological and clinical evidence regarding interactions with warfarin |
| Q36477328 | Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism |
| Q92854767 | Occurrence of Antithrombotic Related Adverse Events in Hospitalized Patients: Incidence and Clinical Context between 2008 and 2016 |
| Q38736964 | Omega-3 fatty acids as an adjunct for periodontal therapy-a review |
| Q90029274 | Optimizing quality care for the oral vitamin K antagonists (VKAs) |
| Q34252907 | Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q37900185 | Oral anticoagulant-associated intracerebral hemorrhage |
| Q38194842 | Oral anticoagulants for Asian patients with atrial fibrillation |
| Q38068455 | Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts |
| Q38972270 | Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants |
| Q50868097 | PGWD: Integrating Personal Genome for Warfarin Dosing. |
| Q41462581 | PGWD: integrating personal genome for warfarin dosing |
| Q48716141 | Participant perspectives from the Indian Health Service Anticoagulation Training Program. |
| Q86604216 | Participation of iatrogenically coagulopathic patients in wilderness activities |
| Q40175981 | Patient Characteristics and Antithrombotic Prescribing Patterns in Patients With Atrial Fibrillation in Tasmania |
| Q37867275 | Patient factors that influence warfarin dose response |
| Q38932177 | Personalized Dose Finding Using Outcome Weighted Learning |
| Q37794005 | Personalized medicine: understanding probabilities and managing expectations |
| Q44027927 | Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital. |
| Q38253820 | Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists |
| Q35870028 | Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials |
| Q37212206 | Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians |
| Q37495788 | Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents |
| Q46093748 | Pharmacological adherence to oral anticoagulant and factors that influence the international normalized ratio stability |
| Q42702460 | Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction |
| Q33663404 | Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results |
| Q34551073 | Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation |
| Q51369422 | Plasma Vitamin K1 Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case-Control Study. |
| Q37874499 | Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic |
| Q33417203 | Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism |
| Q43977905 | Possible antiretroviral therapy-warfarin drug interaction |
| Q38099610 | Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review |
| Q38893410 | Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor |
| Q45332279 | Potential drug-drug interactions within Veterans Affairs medical centers |
| Q37268706 | Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country |
| Q51861211 | Potentially serious drug-drug interactions among community-dwelling older adult dental patients. |
| Q47752166 | Predicting drug interactions in addiction treatment. |
| Q44993649 | Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes |
| Q36258652 | Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol |
| Q45329493 | Predictors of unstable anticoagulation in African Americans |
| Q45972265 | Predisposing preventable factors in patients with bleeding due to warfarin usage: Evaluation of 114 patients. |
| Q42745596 | Preemptive dose reduction of warfarin in patients initiating metronidazole |
| Q33370507 | Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients |
| Q46032921 | Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. |
| Q37121326 | Primary prevention of venous thromboembolism in long-term care: identifying and managing the risk |
| Q42794726 | Probable interaction between warfarin and bee pollen |
| Q53146777 | Probable warfarin and dapsone interaction. |
| Q37762496 | Progress toward genetic tailoring of heart failure therapy |
| Q33348847 | Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review |
| Q41907010 | Quality of anticoagulation therapy in neurological patients in a tertiary care hospital in north India |
| Q80203500 | Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands |
| Q48710599 | R- and S-Warfarin Were Transported by Breast Cancer Resistance Protein: From In Vitro to Pharmacokinetic-Pharmacodynamic Studies. |
| Q37945636 | Raltitrexed in mesothelioma |
| Q35009893 | Raltitrexed: optimism and reality |
| Q53032866 | Randomized clinical study of the peri-implant healing to hydrophilic and hydrophobic implant surfaces in patients receiving anticoagulants. |
| Q60046275 | Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants |
| Q37606536 | Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban |
| Q37809631 | Reliability and validity of 5 databases for the identification of warfarin-medication interactions |
| Q26740248 | Reversal agents for NOACs: Connecting the dots |
| Q35675142 | Review of cases of patient risk associated with ginseng abuse and misuse |
| Q33447738 | Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study |
| Q90722659 | Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication |
| Q37784486 | Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. |
| Q34737465 | Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry |
| Q58703008 | Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study |
| Q40667772 | Role of anticoagulation in neurological practice |
| Q89924903 | Role of direct oral anticoagulants in patients with kidney disease |
| Q37899153 | Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation |
| Q64987142 | Seizure in cerebral venous and sinus thrombosis. |
| Q35650380 | Selecting antithrombotic therapy for patients with atrial fibrillation |
| Q33978811 | Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. |
| Q53244408 | Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. |
| Q37827756 | Stroke prevention in atrial fibrillation: atrial appendage closure |
| Q54296320 | Structure-activity relationships of 3,3'-phenylmethylene-bis-4-hydroxycoumarins: selective and potent inhibitors of gram-positive bacteria. |
| Q40672590 | Study of warfarin utilization in hospitalized patients: analysis of possible drug interactions. |
| Q38728028 | Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? |
| Q42346446 | Synthesis and biological activity of the novel indanedione anticoagulant rodenticides containing fluorine |
| Q35601190 | Synthesis of molecularly imprinted polypyrrole as an adsorbent for solid-phase extraction of warfarin from human plasma and urine |
| Q41247063 | Synthesis, characterization, in vitro antimicrobial, and U2OS tumoricidal activities of different coumarin derivatives. |
| Q36598763 | Systematic overview of drug interactions with antidepressant medications |
| Q36396649 | The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants |
| Q42152671 | The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study |
| Q54961174 | The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. |
| Q45954220 | The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. |
| Q28200551 | The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US |
| Q39254072 | The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective |
| Q38984688 | The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective |
| Q38610543 | The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. |
| Q37809106 | The dental patient on oral anticoagulant medication: a literature review |
| Q38829586 | The discovery of dabigatran etexilate for the treatment of venous thrombosis |
| Q45716615 | The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy |
| Q50095668 | The effect of lycopene on cytochrome P450 isoenzymes and P-glycoprotein by using human liver microsomes and Caco-2 cell monolayer model. |
| Q35073505 | The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study |
| Q40907461 | The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme |
| Q53159003 | The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. |
| Q36762797 | The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans |
| Q43609145 | The need for multicentre cardiovascular clinical trials in Asia |
| Q35120731 | The need for translational research on drug-drug interactions |
| Q42976371 | The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype |
| Q38080765 | The pharmacology and therapeutic use of dabigatran etexilate |
| Q37873969 | The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. |
| Q34200428 | The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes |
| Q58094797 | The research of synthesis and bioactivity of the novel indanedione anticoagulant rodenticides |
| Q21285050 | The safety of cruciferous plants in humans: a systematic review |
| Q26828439 | The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery |
| Q35071798 | The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range? |
| Q46461328 | Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study |
| Q39143375 | Topical Antimycotics for Oral Candidiasis in Warfarin Users |
| Q88395076 | Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation |
| Q37686931 | Updates on the clinical evidenced herb-warfarin interactions |
| Q38496232 | Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice |
| Q34099930 | Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective |
| Q38998384 | Use of novel oral anticoagulant agents in venous thromboembolism |
| Q87056045 | Use of novel oral anticoagulants in patients with heart failure |
| Q35415257 | Using highly variable warfarin dosing to identify patients at risk for adverse events |
| Q54940282 | Vitamin K antagonist use and renal function in pre-dialysis patients. |
| Q37608565 | Vitamin K antagonist use in the elderly: special considerations |
| Q24194649 | Vitamin K for improved anticoagulation control in patients receiving warfarin |
| Q24202915 | Vitamin K for improved anticoagulation control in patients receiving warfarin |
| Q36828712 | Vitamin K-dependent carboxylation of osteocalcin: friend or foe? |
| Q37548255 | Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions |
| Q47880838 | Warfarin Interaction With Hepatic Cytochrome P-450 Enzyme-Inducing Anticonvulsants. |
| Q37607493 | Warfarin and atrial fibrillation: from ideal to real the warfarin affaire |
| Q34566453 | Warfarin and its interactions with foods, herbs and other dietary supplements |
| Q34026225 | Warfarin and vitamin K intake in the era of pharmacogenetics |
| Q24186324 | Warfarin initiation nomograms for venous thromboembolism |
| Q24201274 | Warfarin initiation nomograms for venous thromboembolism |
| Q24240381 | Warfarin initiation nomograms for venous thromboembolism |
| Q45934897 | Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. |
| Q37122112 | Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin |
| Q24647605 | Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding |
| Q34580625 | Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system |
| Q46883875 | Warfarin-drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate. |
| Q43142321 | Warfarin-flucloxacillin interaction presenting as cardioembolic ischemic stroke |
| Q39611447 | Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole |
| Q29644511 | Warfarin: history, tautomerism and activity |
| Q37130019 | Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? |
| Q37272523 | What affects anticoagulation control in patients taking warfarin? |
| Q57631427 | l-Proline catalyzed multicomponent one-pot synthesis of gem-diheteroarylmethane derivatives using facile grinding operation under solvent-free conditions at room temperature |
Search more.